Lumigan belongs to the medicinal group of prostamides. Prostamides have a number of uses in medicine, one of which is the expansion of the channels for the intraocular fluid outflow. Lumigan, thus, copes with its task of reducing intraocular pressure, facilitating the outflow of excess intraocular fluid.
Mechanism of action
The mechanism of action, due to which bimatoprost reduces intraocular pressure in humans, is to increase the outflow of intraocular fluid through the trabecular meshwork and increase the outflow from the uveoscleral parts of the eye. The decrease in intraocular pressure begins approximately 4 hours after the first application. The maximum effect is achieved within about 8-12 hours. The effect duration is at least 24 hours.
Bimatoprost is a potent intraocular pressure lowering agent. Bimatoprost belongs to the group of synthetic prostamide, in terms of chemical structure – to prostaglandin F2α (PGF2α), does not affect any of the known types of prostaglandin receptors. Bimatoprost selectively imitate the effects of a newly invented biologically synthesized substance called prostamides. However, the prostamide receptor has not yet been structured.
During the 12-month study of the Lumigan use at a dose of 0.1 mg / ml in adults in the form of eye drops, the average daily values of intraocular pressure, determined at each visit to the doctor during the entire 12-month study period, differed by no more than 1, 1 mm Hg Art. throughout the day and never exceeded 17.7 mm Hg. Art.
In the course of in vitro studies, bimatoprost penetrated well into the iris and sclera of humans. When put it into the eye in adults, the systemic effect of bimatoprost is very low. Systemic cumulation was not observed. When putting on a solution of bimatoprost, 1 drop in both eyes once a day for 2 weeks, Cmax of bimatoprost in blood plasma was reached within 10 minutes after application and decreased to the lowest level of determination (0.025 ng / ml) within 1.5 h after application.
Eye drops, solution 0.1 mg / ml vial-drop. 3 ml, No. 1. Bimatoprost 0.1 mg / ml.
Other ingredients: benzalkonium chloride, sodium hydrogen phosphate heptahydrate, citric acid monohydrate, diluted hydrochloric acid or sodium hydroxide, purified water.
Indications for use
Decrease in increased intraocular pressure in adult patients with chronic open-angle glaucoma and intraocular hypertension (as monotherapy or additional therapy to β-adrenergic receptor blockers).
Mode of application
Lumigan eye drops are used once a day. Wash hands before use. Tilt your head back and pull the lower eyelid slightly downward to create space between the eyelid and eye.
Look away from the pipette and put one drop in the space between the eyelid and the eye and close the eyes.
Keep eyes closed for about a minute to prevent dripping.
Before using Lumigan, you must remove contact lenses, since the drug contains preservatives that can be absorbed by the lenses. Lenses can be put within 15 minutes after using the drops.
Do not touch the pipette with any surfaces (eyes or hands) to avoid contamination of the pipette and the occurrence of eye infections.
Hypersensitivity to the active substance or excipients that make up the drug, including benzalkonium chloride.
- Dry eyes;
- Visual impairment;
- Burning sensation in the eyes;
- Foreign body sensation;
- Darkening of eyelashes;
- Feeling irritated;
- Swelling of the conjunctiva;
- Secretions from the eyes;
- Pigmentation of the iris.
Bimatoprost solution may cause gradual discoloration of the eyes, eyelids and eyelashes. These changes are very minor and may not be noticeable for several years. Changes usually occur in the eye being treated, which can lead to cosmetic eye differences.
Pregnancy and breastfeeding
The consequences of using Lumigan during pregnancy and lactation have not been properly studied. There is no data on whether Lumigan is excreted in breast milk. Therefore, it may be recommended to stop breastfeeding during the period of treatment with Lumigan.
Lumigan should be used during pregnancy only if absolutely necessary, when the expected benefit to the mother outweighs the potential risk to the fetus.
The consequences of using these drops in children have not been studied, therefore Lumigan is not prescribed for children.
Interaction studies were not performed. Interaction in humans is not expected, since systemic concentrations of bimatoprost are extremely low (<0.2 mg / ml) in the body after using bimatoprost solution at a dose of 0.3 mg / ml in the form of eye drops.
Preclinical studies indicate that bimatoprost is biotransformed in the body using any of the numerous enzymes and metabolic pathways and does not affect the liver enzymes involved in the metabolism of drugs.
In the course of clinical trials, bimatoprost solution in the form of eye drops was used simultaneously with several different ophthalmic beta-adrenergic blockers (timolol 0.5%) without signs of interaction.
The simultaneous use of Lumigan and drugs for the treatment of glaucoma, except for topical blockers of beta-adrenergic receptors, has not been studied in the course of additional therapy for glaucoma.
It does not require special storage conditions. The shelf life of the drug after the first opening of the bottle is 28 days.